S-1: Waystar Holding Corp. Files S-1 for Secondary Offering of 12.5 Million Shares

Waystar Holding Corp. announces a secondary offering of 12.5 million shares of common stock by selling stockholders, with no proceeds to the company.

Summary

• Waystar Holding Corp. has filed a Form S-1 registration statement for a secondary offering.
• The offering involves 12,500,000 shares of common stock being sold by existing stockholders.
• The company will not receive any proceeds from this sale.
• Underwriters have a 30-day option to purchase an additional 1,875,000 shares from the selling stockholders.
• The offering is led by J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Barclays Capital Inc.
• As of May 12, 2025, Waystar's common stock was priced at $40.30 per share on the Nasdaq Global Select Market under the symbol WAY.
• EQT, CPPIB, and Bain will beneficially own approximately 19.3%, 14.8%, and 10.8%, respectively, of Waystar's common stock after the offering.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily providing factual information about the secondary offering. While it highlights Waystar's strengths, it also acknowledges potential risks, resulting in a balanced sentiment score.

Risks

• The document references a detailed 'Risk Factors' section in the prospectus and the company's Annual Report on Form 10-K, highlighting potential risks associated with investing in Waystar's common stock.
• The Institutional Investors will continue to hold a significant percentage of our outstanding common stock after this offering and their interests may be different than the interests of other holders of our securities.
• We are an emerging growth company and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors.
• Failure to comply with requirements to design, implement, and maintain effective internal controls could have a material adverse effect on our business and stock price.
• The market price of our common stock has been volatile and may continue to fluctuate substantially, which could result in substantial losses for purchasers of our common stock.
• Your percentage ownership in us may be diluted by future issuances of our common stock, which could reduce your influence over matters on which stockholders vote.
• Because we have no current plans to pay cash dividends on our common stock, you may not receive any return on investment unless you sell your shares of common stock for a price greater than that which you paid for it.
• Future sales, or the perception of future sales, by us or our existing stockholders in the public market following the completion of this offering could cause the market price for our common stock to decline.
• If securities analysts do not publish research or reports about our business or if they downgrade our stock or our sector, our stock price and trading volume could decline.
• Anti-takeover provisions in our organizational documents could delay or prevent a change of control.
• Our board of directors is authorized to issue and designate shares of our preferred stock in additional series without stockholder approval.
• Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or if such court does not have jurisdiction, another state or the federal courts (as appropriate) located within the State of Delaware) will be the sole and exclusive forum for certain stockholder litigation matters, which could limit our stockholders ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees, or stockholders.

Future Outlook

The company expects to continue to grow its market share by virtue of its differentiated platform and capabilities and expects to expand its TAM further over time as it develops new solutions and address adjacent workflows.

Industry Context

The document highlights the complexity of the healthcare payment ecosystem and the administrative burden faced by healthcare providers, positioning Waystar as a solution provider in this evolving market.

Comparison to Industry Standards

• The document states that Waystar's platform significantly outperforms those of its competitors, who lack either modern functionality or the ability to address the full end-to-end payments workflow.
• Waystar had an 83% win rate against its competitors for fiscal years 2022 through 2024 in situations where the client ultimately elected to switch vendors or purchase a new solution.
• Waystar ranked #1 in client satisfaction with implementation time versus competitors, 94% of clients are satisfied with our integrations with other systems, and 98% of clients say we deliver on trust very well or extremely well.
• Waystar ranked #1 in satisfaction with rate of product innovation and vision versus competitors, and 94% of clients are satisfied with our capabilities in automation.

Stakeholder Impact

• The secondary offering provides liquidity for existing shareholders.
• The offering could potentially dilute existing shareholders if the underwriters exercise their option to purchase additional shares.
• The company's operations and strategy are not directly impacted by the secondary offering, as it will not receive any proceeds.

Key Dates

Keywords

secondary offering, common stock, Waystar Holding Corp, underwriters, registration statement, selling stockholders, shares, Nasdaq